Purpose To compare hepatic parenchymal contrast media (CM) enhancement during multi-detector row computed tomography (MDCT) and its correlation with volume pitchcorrected computed tomography dose index CTDI vol ) and body weight (BW). Material and methods One hundred patients referred for standard three-phase thoraco-abdominal MDCT examination were enrolled. BW was measured in the CT suite. Forty grams of iodine was administered intravenously (iodixanol 320 mg I/ml at 5 ml/s or iomeprol 400 mg I/ml at 4 ml/s) followed by a 50-ml saline flush. CTDI vol presented by the CT equipment during the parenchymal examination was recorded. The CM enhancement of the liver was defined as the attenuation HU of the liver parenchyma during the hepatic parenchymal phase minus the attenuation in the native phase. Results Liver parenchymal enhancement was negatively correlated to both CTDI vol (r=−0.60) and BW (r=−0.64), but the difference in correlation between those two was not significant.
Introduction
Iodine contrast media (CM) are used during computed tomography (CT) to enhance attenuation differences between normal and pathological tissues. In order to reduce the risk of nephrotoxic effects from CM, the amount given should be minimized, but be sufficient to provide a diagnostic examination. CM enhancement in Hounsfield units (HU) is closely related to CM dose, injection rate and patient-related factors such as cardiac output and body size. Apart from body weight (BW), several other body size parameters have been used to optimize CM dosage such as body height (BH), ideal body weight (IBW), lean body mass (LBM), body surface area (BSA) and body mass index (BMI). Some studies have shown that, albeit small, BSA has an advantage over BW [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .
Modern CT systems are equipped with automatic dose modulation based on "scout images", a plain twodimensional radiograph obtained by the CT immediately prior to the helical examinations. The estimated average absorbed radiation dose within the planned examination volume is presented as volume pitch-corrected computed tomography dose index volume (CTDI vol ) [11] [12] [13] .
There is a strong relationship between CTDI vol and body size [14] . To our knowledge no previous study has evaluated the relationship between expected CTDI vol and parenchymal CM enhancement. If there is a correlation between CTDI vol and parenchymal CM enhancement comparable to that of BW, it has the potential to simplify individualized CM dosage at CT. Thus, the aim of this study was to compare the correlation of CTDI vol and BW with the CM enhancement in liver during the parenchymal phase.
Material and methods

Patients
The study was approved by the local ethics committee and included 100 patients (42 women) referred for thoracoabdominal CT between November 2008 to June 2010 (group 1) and another 20 patients were recruited in January and February 2014 (group 2). The patient characteristics are presented in Table 1 . Part of the same study material (group 1), not including CTDI vol , has previously been presented [15] .
Patient BW in light clothing was measured at the time of the examination in the CT suite using a medical balance (Soehnle Professional GmbH, Germany). Height was measured in the examination room using a wall-mounted ruler. After the examination, the CTDI vol of the parenchymal hepatic phase was automatically given by the CT software and archived in the local picture archival system (PACS).
CT protocols and CM injection
All patients were examined by using a 64-detector row CT equipment (General Electric Light Speed VCT XT, GE Healthcare, Milwaukee, Wisconsin, USA). Imaging parameters were as follows: 120 kVp, automatic dose modulation (Smart mA, Auto mA), 64×0.625 mm detector collimation and 0.5 s rotation time. The thoraco-abdominal examination protocol included three-phase imaging: (1) native phase of the liver with a noise index (NI) of 50 and a pitch of 1.375, (2) CM phase of the thorax and abdomen timed for the portal venous inflow phase (late arterial phase, NI 36 and pitch 0.984) of the liver and (3) abdomen in the hepatic parenchymal CM phase (NI 36 and pitch 0.984). The examination start for the CM phases was defined by use of bolus tracking technique (Smart prep) with the region of interest (ROI) placed in the aortic arch, a threshold level of 150 HU, 20 s delay for the portal venous inflow phase and the hepatic parenchymal phase started 25 s after the end of the portal venous acquisition. The imaging volume at the parenchymal phase started 2 cm above the hemidiaphragms including the whole liver and ended at the symphysis pubis. The reconstruction image thickness was 5 mm with 2.5 mm reconstructed overlap in all three phases.
A 16-gauge peripheral venous access was inserted into an antecubital vein. The CM used was iodixanol 320 mg I/ml (Visipaque®-320, GE Healthcare, Chalfont St. Giles, UK) or iomeprol 400 mg I/ml, (Iomeron®-400, Bracco Imaging SpA, Milan, Italy). For group 1 both types of CM 40 grams of iodine (g I) were administered with a power injector (Medrad, Stellant Dual Head Injector, Pittsburgh, Pennsylvania, USA) during 25 s, i.e. a total volume of 125 ml iodixanol was injected at 5 ml/s and 100 ml of iomeprol at 4 ml/s resulting in 1.6 g I/s for both CM. The CM injections were followed by a 50-ml saline flush. For group 2 the CM dose was individually adjusted depending on CTDI vol. The CM dose was adjusted so that 95 % of the patients would obtain a hepatic enhancement of 50 HU during the hepatic phase.
Quantitative image analysis
All examinations were sent to a dedicated workstation (Advantage work station 4.5, GE Healthcare, Milwaukee, Wisconsin, USA). The mean attenuation in Hounsfield units (HU) for the native and hepatic parenchymal phase was determined by using a 10-mm circular ROI placed in the liver at the level of (a) the liver hilum (Fig. 1) , (b) 3 cm caudal to the hemidiaphragm and (c) 3 cm cranial to the caudal edge of the liver. Care was taken to avoid visible vessels and heterogeneous areas of the liver. The mean value of the three measurements was used for correlation with BW and CTDI vol .
Statistical analysis
All statistical analyses were conducted in SPSS Statistics release 20.0.0 (IBM Corp.). Linear regression analysis was used with liver enhancement as dependent variable and with either CTDI vol or body weight as the main independent variable. Gender (male/female), height and age on continuous scales were added as covariates. As a final step, we also evaluated the effect of including both CTDI vol and body weight simultaneously. Statistical significance was assessed using the Wald test with p<0.05 as threshold. Adjusted r 2 was used as a measure of the proportion of explained variance in the regression models.
Results
The correlations between CTDI vol and hepatic parenchymal CM enhancement and between BW and hepatic enhancement are summarized in Table 2 .
CTDI vol correlated significantly with liver CM enhancement (r=−0.60, adjusted r 2 =0.35; p<0.001, Fig. 2 ). The proportion of explained variance in liver enhancement increased significantly when gender (adjusted r 2 =0.37; p= 0.04) was added to the regression model. No further improvement was seen when age was added (p=0.25).
Alternatively, the variation in liver enhancement could be explained by body weight only (r=−0.64, adjusted r 2 =0.40; p<0.001). Adding gender (p=0.65), height (p=0.19), age (p= 0.45) or CTDI vol (p=0.42) did not improve the proportion of explained variance further.
The difference in correlation to liver CM enhancement between CTDI vol and BW was not significant.
The equation for individually adjusting CM dose in group 2 using CTDI vol was calculated as follows: The median CM enhancement in liver for group 2 was 67.5 (55-96) HU. In no patient was a liver CM enhancement less than 50 HU achieved and no relationship between liver CM enhancement and BW could be observed after CM dose adjustment, for the whole group nor when subgrouped for gender (Fig. 3) .
Discussion
In this study the CM enhancement of the liver in the parenchymal phase was shown to be related to CTDI vol . This was comparable to the relationship to BW, which implies that CTDI vol may be used instead of BW when adjusting CM dose for patient size. This would make it possible to automate the individual dosage of CM.
During recent years, the collaboration between vendors of CT systems and CM injectors has led to the integration of injector software into the CT software. This includes the possibility to save dedicated injection protocols connected to imaging protocol, adjustment of the amount and injection rates of CM and saline, and enables mixed saline and CM injections. It may therefore be speculated that the obtained CTDI vol , calculated from the scout images to adjust exposure parameters, might also be used to automatically calculate the individual CM dose to be injected. This would remove the need for obtaining accurate patient weight prior to the examination and improve patient workflow.
CTDI vol varies with the NI used. This means that the CTDI vol will increase when a high radiation dose protocol is used and decrease for low dose protocols. When adjusting the Fig. 1 A 10 -mm circular ROI placed in the liver at the level of the liver hilum Table 2 Correlation between CM liver enhancement and body weight or CTDI vol for all, women and men. The differences in correlation between body weight and CTDI vol to CM liver enhancement were not significant CM dose for body size using CTDI vol a normalized NI should be applied. Thus, CTDI vol is simply used as a "body densitometry" of the examined patient.
The hypothesis that CM dose can be automatically adjusted for body size by using CTDI vol was successfully tested in 20 patients. After CM dose adjustment there was no remaining relationship between BW and liver CM enhancement (Fig. 3) . A liver CM enhancement greater than 50 HU was obtained in all patients. However, this test was just made to prove the feasibility of the concept, and a larger study comparing the efficacy of different contrast media strategies is ongoing.
Our study has several limitations. To enable the hypothesized automation of CM dosage CTDI vol has to be calculated from the scout view obtained prior to the examination. In this study, the CTDI vol data used for group 1 was obtained from the actual exposure during the parenchymal phase, not from the scout images. These data can evidently not be used for the calculation of CM doses. However, our experience of the 50 patients monitored is that the prediction of actual exposed CTDI vol from the scout images is very strong and differs less than 0.004 % (CTDI vol range 2.88-16.44 mGy, patient details not shown). There is also a risk that the patient has metal implants or that the patient cannot raise their arms, which will lead to falsely high CTDI vol estimations. Such methodological errors should be possible to reduce by automatic pattern recognition and subsequent adjustment. Fig. 2 Relationship between CTDI vol and liver contrast media (CM) enhancement during the parenchymal phase in 100 patients receiving 40 g of iodine Fig. 3 Relationship between body weight and liver contrast media (CM) enhancement during the parenchymal phase in 20 patients in whom the given amount of iv iodine was adjusted for using CTDI vol To conclude, the correlation between CTDI vol and liver parenchymal enhancement may indicate that it may replace BW when adjusting CM doses to body size. This makes it potentially feasible to automatically individualize CM dosage by CT.
